Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

InSphero to Distribute Dainippon Screen Imager for Rapid Profiling of 3D Microtissues

Published: Tuesday, April 08, 2014
Last Updated: Tuesday, April 08, 2014
Bookmark and Share
The Cell'iMager, to be marketed in the US and Europe, simplifies growth and morphological profiling of 3D microtissues.

InSphero AG and Dainippon Screen (Kyoto, Japan) announced today they have reached a
distribution agreement for InSphero to begin marketing Dainippon Screen's Cell'iMager in North
America and Europe. Dainippon Screen selected InSphero based on their in-depth know-how
pertaining to 3D microtissue biology and applications. The CelriMager is fully compatible with
InSphero's GravityTRAPTm 3D microtissue assay platform and other 3D-cell culture plates,
providing rapid, robust profiling of microtissue growth and morphology.

3D tumor microtissues or spheroids are increasingly used in drug discovery and development as
a more representative biological model for testing drug sensitivity and efficacy. Size and
morphology are important determinants to evaluate the biological behavior of 3D microtissues,
particularly in development of anti-cancer drugs, where monitoring cell growth is a particularly
critical endpoint. High-throughput, accurate assessment of 3D microtissue size and growth in
these applications is currently limited by sequential, time-consuming and often manual optical

The innovative CelriMager's high-resolution scanning optics provide rapid direct measurement
of multiple endpoints, including microtissue diameter, area, pseudo-volume, and circularity at a
resolution of up to 9600 dpi. The system can analyze four 96- or 384-well plates in a single run,
in as little as one minute per plate, enabling fast and label-free visualization of even small size
differences. The scanner software is tailored for the analysis of 3D microtissues, allowing
adjustment of parameters such as focal plane, minimum and maximum object size, scan area,
and resolution for developing protocols specific to a given tissue type or assay.
The instrument is already broadly used in Japan and is now available in North America and
Europe through InSphero's experienced sales team.

InSphero CEO and co-founder Dr. Jan Lichtenberg sees the agreement as an exciting next step
toward making InSphero a total solution provider for the 3D cell culture marketplace. "Adding
the Cell3iMager to our portfolio gets us closer to offering our customers a complete set of
solutions for 3D cell based assays — from the assay-ready 3D cell model, to assay reagents and
instruments for endpoint analysis."

Mr. Kunihisa Hashimoto, General Manager of Dainippon Screen's Imaging and Solutions
Division, noted the agreement with InSphero is also a major step for Dainippon Screen.
"Combining InSphero's GravityTRAPTm plates and microtissues with the imaging technology of
our Cell'iMager is sure to streamline and simplify research using 3D tissue cultures. We are
excited to leverage InSphero's expertise in the 3D marketplace to help bring our innovative
imaging system to North America and Europe."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms
PerkinElmer named as exclusive distributor of InSphero 3D culture technology.
Thursday, August 06, 2015
InSphero AG Secures CHF 20 Million Series C Financing
3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Wednesday, July 15, 2015
InSphero AG Secures CHF 20 Million Series C Financing
Leading 3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Tuesday, July 14, 2015
InSphero Publishes 3D Tumor-Stroma Model for Non-Small Cell Lung Cancer
PLOS One article delivers promising co-culture method to mimic tumor microenvironment, demonstrating potential for biomarker and drug discovery.
Thursday, April 24, 2014
InSphero Announces Collaboration with NCATS
Study to characterize 460 NCATS anti-cancer agents in 3D tumor models generated using InSphero technology.
Friday, March 21, 2014
Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos